Status:

COMPLETED

Candesartan Versus Propranolol for Migraine Prevention

Lead Sponsor:

Norwegian University of Science and Technology

Collaborating Sponsors:

AstraZeneca

St. Olavs Hospital

Conditions:

Migraine Without Aura

Migraine With Aura

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

PHASE3

Brief Summary

The main aim of the present study is to compare candesartan with propranolol for migraine prophylaxis.

Detailed Description

Candesartan was shown to be effective for migraine prophylaxis in a randomized double blind cross-over study published in 2003. The drug is now widely used for this purpose in many countries, although...

Eligibility Criteria

Inclusion

  • age 18 to 65 years
  • retrospectively have ≥ 2 migraine attacks per month during the last 3 months
  • during the baseline period have ≥ 2 migraine attacks
  • debut of migraine at least one year prior to inclusion
  • start of migraine before age 50 years.

Exclusion

  • interval headache not distinguishable from migraine
  • chronic tension-type headache or other headache occurring on ≥ 15 days/month
  • pregnancy, nursing or inability to use contraceptives
  • heart conduction block on ECG or significant ECG abnormality on inclusion
  • heart rate \< 54 after 3 minutes rest
  • previous or present asthma, diabetes; decreased hepatic or renal function
  • hypersensitivity to active substance
  • history of angioneurotic edema
  • significant psychiatric illness
  • use of daily migraine prophylactics less than 4 weeks prior to start of study
  • having tried ≥ 3 prophylactic drugs against migraine during the last 10 years
  • previous use of propranolol or candesartan in adequate doses
  • previous discontinuation of either Atacand or Inderal Retard (or another beta blocker) due to side effects
  • current use of antihypertensive medication
  • require use of rizatriptan (Maxalt) 10 mg tabl.
  • subjects requiring detoxification from acute medication (ergotamines, opioids)
  • patients who consistently fail to respond to any acute migraine medication
  • patients with alcohol or illicit drug dependence

Key Trial Info

Start Date :

April 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2012

Estimated Enrollment :

72 Patients enrolled

Trial Details

Trial ID

NCT00884663

Start Date

April 1 2009

End Date

March 1 2012

Last Update

December 24 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Norwegian National Headache Centre, St. Olavs University Hospital

Trondheim, Norway, 7489